Megan E. McMahon

Pfizer
Senior Director and Team Leader, Global CMC
Megan E. McMahon is a Senior Director in Global CMC at Pfizer in Connecticut. Megan received her BSc in chemistry from Purdue University and an MSc in regulatory affairs/quality assurance from Temple University. Megan started at Pfizer in chemical R&D as an analytical chemist and has worked in regulatory CMC for the past 14 years. She is a member of Pfizer’s Impurity Council and stability Council. Megan was a founding member of the AAPS Chemical and Biological API Focus Group in 2009 and served as Chair in 2012 and 2013. She is an active member of the AAPS CMC Community Steering Committee and has taken a leading role on the AAPS Virtual Round Table series. Megan is an active member of the IQ Risk Based Predictive Stability Working Group and leads the IQ Lean Stability Working Group. She has been an ISPE member since 2019.

Related Articles

A Patient-Centric Review of ICH Q6A and ICH6B
Online Exclusives
A Patient-Centric Review of ICH Q6A and ICH6B

The ICH Quality Discussion Group (QDG) has recommended contemporizing the specification setting guidelines ICH Q6A and Q6B. This provides an excellent opportunity to update ICH Q6A/B to align and work in a complementary manner with the science-, risk/knowledge-based concepts in ICH Q8–Q12. The ISPE Pharmaceutical Quality Lifecycle Implementation (PQLI) Patient-Centric Specification working...

A Proposal for a Comprehensive Quality Overall Summary
Features
A Proposal for a Comprehensive Quality Overall Summary

When working with the common technical dossier (CTD), the structure of Module 2 “follows the scope and outline of the Body of Data in Module 3,”1

  • 1International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. “Concept Paper: M4Q(R2) Common Technical Document on Quality Guideline.” Published 15 November 2021.
Reporting categories for changes in the drug substance (DS) and drug product (DP) process and analytical methods per FDA guidance [
Features
Case Study: Facilitating Efficient Life-Cycle Management via ICH Q12

The latest ICH guideline, ICH Q12,1

  • 1International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. “ICH Harmonised Guideline: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management. Q12. Final Version.” 20 November 2019.